ERT, the global provider of health outcomes services taken private last year by affiliates of Genstar Capital, has consolidated its position as a leading provider of eClinical trial solutions in Japan by achieving two important milestones.
The Philadelphia, US-based company has completed registration for Kabushiki Kaisha (KK) status – indicating a direct corporate presence in Japan – and has set up a fully-owned local subsidiary, ERT Asia Group, Ltd.
In legal terms, a KK is equivalent to a joint-stock corporation in the US and is subject to requirements such as a registered office in Japan, registered directors and a minimum number of issued shares.
KK registration will enable ERT to broaden the range of local services it offers in Japan while establishing a “solid foundation” to expand its Asian presence, the company noted.
Accordingly, ERT will expand its local resources working directly with customers in Japan on the deployment of nationally based projects. That will also be reflected in the quality of local services, it added.
The company’s solutions have already been used in more than 1,200 studies in Asia, with growing demand from biopharmaceutical companies conducting trials across the region.
ERT has also launched a local version of its corporate website (www.ertjapan.jp) to help Japanese biopharmaceutical researchers access information about the company’s eClinical trial solutions and capabilities as well as current job opportunities.
“Increasing the number of local ERT resources will enable us to work more collaboratively with our customers and our excellent partners in Japan and other Asian countries to increase efficiencies in study execution and improve the integrity of data collected in clinical research,” commented Robert Brown, the company’s vice president, business development Asia-Pacific.